6585 POSTER Phase II Study of Low-dose Everolimus Plus Weekly Cisplatin and 24-hour Infusion of High-dose 5-fluorouracil and Leucovorin for First-line Treatment of Metastatic or Recurrent Gastric Cancers

Abstract

the triplet therapies containing capecitabine as compared with fluorouracil and for those containing oxaliplatin as compared with cisplatin. Results: The hazard ratio for death in the capecitabine group was 0.88 (95% confidence interval [CI], 0.81 to 0.98) in comparison to fluorouracil and the hazard ratio for the oxaliplatin group was 0.93 (95%CI, 0.82 to 1.10) in comparison to cisplatin. Median survival times in the ECF, ECX, EOF, and EOX groups were 9.2 months, 9.3 months, 9.1 months, and 11.5 months, respectively; survival rates at 1 year were 36.6%, 38.9%, 40.1%, and 47.5%, respectively. Overall survival was longer with EOX than with ECF. Toxic effects of capecitabine and fluorouracil were almost similar. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity but with slightly higher incidences of neuropathy. Conclusions: In our experience, oxaliplatin and capecitabine are more effective than cisplatin and fluorouracil, respectively, in patients with previously untreated esophagogastric cancer.